Treatment of chronic hepatitis C with recombinant human interferon-α2a: Results of a randomized controlled clinical trial
G. Diodati, A. Ruol(University of Padua), Massimo Rugge(University of Padua), F. Tremolada, Franco Noventa(University of Padua), L Pollice(University of Bari Aldo Moro), Sergio Scaccabarozzi(Roche (Switzerland)), A. Tagger(University of Milan), Cristina Davite(Nerviano Medical Sciences), G. Realdi(University of Padua), Paola Bonetti(Center for Pediatric Endocrinology Zurich), C. Casarin(University of Verona)
Cited by 73
Related Papers
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
|Blood|2002|1.9k
Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
|Gastroenterology|1997|1.4k
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score
|Journal of Thrombosis and Haemostasis|2010|1.2k
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients
|Haematologica|2007|774
Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer
|New England Journal of Medicine|1992|685